When most people hear the word opioid, they think of the brain. For decades, researchers did too. The dominant view was that opioid receptors matter mainly inside the central nervous system, where they dampen pain signals and, unfortunately, also produce sedation, dependence, and a range of other unwanted effects. A recent comprehensive review published in the British Journal of Pharmacology challenges that narrow focus by mapping out what happens when researchers look further downstream, specifically at kappa opioid receptors sitting in peripheral tissues throughout the body.
The kappa opioid receptor, abbreviated KOR, belongs to a large family of proteins called G protein-coupled receptors. These receptors sit on the surface of cells and act like biological switches. When the right molecule binds to them, they trigger a cascade of signals inside the cell. KOR has long been known to play a role in reducing pain sensation and modulating immune activity. What the review highlights is how much of that action occurs outside the brain, in joints, gut tissue, skin, and other peripheral locations, and why that distinction matters enormously for drug development.
The authors synthesize current knowledge on KOR biology at the tissue level, covering molecular signaling, gene expression patterns, genetic variation in the receptor gene, and the latest strategies researchers are using to design compounds that hit peripheral KOR without reaching the brain. Peptide-based ligands, the review notes, have emerged as a particularly promising design approach in this space.
What KOR actually does in the body
KOR is one of three classical opioid receptor types. When researchers activate it, the receptor can reduce pain signaling and dampen inflammatory activity. In the central nervous system, KOR activation also produces side effects that have historically made it a difficult target: dysphoria, sedation, and psychotomimetic effects, meaning perceptual disturbances that resemble aspects of psychosis. Those central effects have kept many KOR-targeting compounds out of clinical use despite their potential anti-pain and anti-inflammatory properties.
The peripheral nervous system tells a different story. Sensory nerve fibers that run through the skin, joints, and organs carry KOR on their surfaces. Immune cells circulating in inflamed tissue also express the receptor. When researchers activate KOR at these peripheral sites in preclinical models, they observe reduced pain signaling and reduced inflammatory activity without the problematic central effects, because compounds designed to stay outside the blood-brain barrier do not reach the areas that generate those side effects.
The review emphasizes that KOR signaling is not a simple on-off switch. The receptor can couple to different intracellular pathways depending on which molecule binds it and in what tissue context. This concept, called pathway-selective or biased signaling, means that two compounds binding the same receptor can produce meaningfully different biological outcomes. Understanding which pathways drive therapeutic effects versus adverse effects is a central theme in current KOR drug discovery research.
Tissue-specific expression and disease regulation
One of the review's contributions is pulling together data on how KOR expression changes across different tissues and disease states. Receptor levels are not fixed. In inflamed tissue, KOR expression can increase, which means the receptor becomes more accessible and potentially more influential in shaping local pain and immune responses. The review describes this as disease-associated regulation, and it helps explain why peripheral KOR targeting might be especially relevant precisely when inflammation is most intense.
The authors highlight specific disease contexts in which altered KOR signaling appears to contribute to pathophysiology. Arthritis, inflammatory bowel disease, and psoriasis each receive attention. In arthritic joints, peripheral sensory neurons and immune cells interact in ways that KOR signaling can modulate. In the gut, KOR-expressing neurons and immune cells in the intestinal wall may influence both pain and the inflammatory environment seen in bowel disease. In psoriatic skin, receptor expression patterns suggest a role in local immune dysregulation. Across all three contexts, the literature points to KOR as a participant in disease processes rather than just a potential drug target layered on top of them.
Genetic variation in the OPRK1 gene
The gene that encodes KOR is called OPRK1. The review discusses how genetic variants in this gene can influence receptor function and pharmacological responses. Some individuals carry sequence differences that alter how the receptor is expressed, how it folds, or how it couples to downstream signaling partners. These variants have implications for understanding why people respond differently to pain stimuli and potentially to compounds targeting KOR.
The field of pharmacogenomics, which studies how genetic variation shapes drug response, has identified OPRK1 variants as relevant to opioid pharmacology more broadly. The review situates this genetic dimension within the peripheral KOR story, noting that tissue-specific expression differences and individual genetic variation together create a complex landscape that researchers must account for when designing and testing KOR-targeting compounds.
Peptide-based ligands as a design strategy
The final section of the review covers drug discovery approaches, and it is here that peptide-based ligands receive particular emphasis. Peptides are short chains of amino acids, the same building blocks that make up proteins. Because they can be engineered with considerable precision to bind specific receptor conformations, they are attractive tools for researchers trying to achieve selectivity for peripheral KOR over central KOR.
One reason peptide compounds are well-suited to peripheral targeting is that they typically do not cross the blood-brain barrier efficiently. Larger, more water-soluble molecules tend to stay outside the central nervous system, which is exactly the property researchers want when the goal is to engage peripheral receptors while leaving central ones alone. The review describes peptide-based approaches as part of a broader set of innovative molecular design strategies that also include small molecules engineered for poor central nervous system penetration and receptor-selective antibody fragments.
Early research into peripherally restricted KOR agonists has shown encouraging signals in preclinical pain and inflammation models. The review frames these findings as rationale for continued investigation, not as evidence of established clinical benefit. The gap between promising preclinical data and validated human outcomes remains significant, and the authors are careful to position this body of work as a foundation for ongoing research rather than a set of ready solutions.
Why the peripheral distinction matters
The core argument running through the review is that location matters when it comes to KOR. A compound that activates the receptor indiscriminately, hitting both central and peripheral populations, inherits the full liability profile of classical opioids at the central level. A compound that reaches only peripheral KOR might retain analgesic and anti-inflammatory properties while shedding much of that liability. The review positions this not as a solved problem but as a tractable one, meaning researchers have identified the right question and are developing the tools to answer it.
This framing has practical implications for how researchers design studies and prioritize compounds. It also explains why the peptide approach has attracted interest: peptides offer a degree of structural tunability that makes it possible to optimize for peripheral restriction alongside receptor selectivity. The review suggests that combining insights from molecular signaling biology, tissue expression data, genetic pharmacology, and medicinal chemistry will be necessary to move the most promising candidates forward.
What the research landscape looks like now
The British Journal of Pharmacology review represents a synthesis of a field that has been building for several years. The authors describe peripheral KOR as a promising and versatile target, language that reflects genuine scientific momentum rather than near-term clinical availability. Most of the compounds discussed remain in early-stage investigation, with preclinical models providing the primary evidence base.
For anyone following peptide research, the KOR story is a useful example of how receptor biology at the tissue level can reframe an entire drug discovery strategy. A receptor considered difficult or dangerous in one context can look quite different when researchers ask where exactly in the body it is being engaged and what downstream signals it is producing in that specific environment. The literature surveyed in this review suggests that peripheral KOR biology is rich enough to support continued exploration across multiple disease areas, with peptide-based ligands occupying a central position in the experimental toolkit.
